TROPICCANA: A new blood test to monitor treatment in patients with cervical cancer

Treatment Response In Cervix Cancer Assessed by circulating HPV DNA

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN17304563

Enrollment

131

Registered

2026-04-17

Start date

2026-01-30

Completion date

Unknown

Last updated

2026-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with locally advanced cervix cancer receiving chemoradiation. Cancer

Interventions

TROPICCANA is a blood and tissue sample collection and data analysis study. It does not involve any additional screening tests, treatments or visits to the hospital. Participants will be asked to dona

Eligibility

Sex/Gender

All

Age

18 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1. Age 18 years or older 2. Patients with histologically confirmed Stage 1B-4A (FIGO 2018) histologically confirmed HPV associated carcinoma of the cervix 3. Planned to receive radical radiotherapy or chemoradiotherapy 4. Treatment and follow-up within the same hospital or centre 5. Ability to give informed consent for biological sample collection

Exclusion criteria

Exclusion criteria: 1. Previous or concurrent illness or situation, which in the investigator’s opinion would interfere with completion of the sample collection 2. Any invasive malignancy within the previous 2 years (other than non-melanomatous skin carcinoma or cervical carcinoma in situ)

Countries

England, United Kingdom

Contacts

Public ContactAgnieszka Niebrzydowska

Agnieszka.Niebrzydowska@rmh.nhs.uk+44 20 8915 6666

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: May 1, 2026